Growth in Sotos syndrome

J C Agwu, N J Shaw, J Kirk, S Chapman, D Ravine, T R P Cole

Abstract
Although there are several reports on infant and childhood growth in patients with Sotos syndrome, there is little information on the final height achieved and puberty. Growth data on 40 patients (20 female and 20 male) aged 2–31 years were collected. These showed that patients with Sotos syndrome are excessively tall at birth, during infancy, and during childhood. Disproportionately long limbs constitute much of the increase in stature. Hormonal delay, with a non-progressive neurological disorder, leads to a mean (SD) final height of 172.9 (5.7) cm in women. This is within the normal range for the population. Most of the men also attained a final height (mean, 184.3 cm; SD, 6.0) within the normal range, although exceptions were more likely in men than in women. Therefore, these results show that most patients with Sotos syndrome do not require intervention to limit their adult height.

Keywords: Sotos syndrome; height; puberty

Patients and methods
Our study had ethics committee approval, and consent was obtained from parents and, where relevant, from the individuals themselves. One of the authors (TC) examined all of the patients to provide consistent confirmation of the diagnosis of Sotos syndrome.

We measured the patient’s height and weight, as well as parent heights, at this visit. In 24 patients, we measured the arm span, as well as the body segment ratios. We measured the arm span (distance between the finger tips of middle fingers of each hand when the arms are stretched out horizontally from the body) using a tape measure. We also measured the lower body segment (distance from the top of the middle part of the pubic bone to the sole of the feet) using a tape measure. We calculated the upper to lower body segment ratios using the following equation:

\[
\text{upper segment} = \frac{\text{height} - \text{lower segment}}{\text{lower segment}}
\]

Methods for measuring arm span and body segment ratios as well as standards for normal children have been published previously.

Subsequently, we obtained other growth data with the help of individual paediatricians and general practitioners.

We obtained the age of menarche in girls by history from parents and from the case records where possible. Two of the authors (SC and JA) assessed all the bone ages individually (using the Tanner Whitehouse 2 (TW2) method), with good agreement between them.

We calculated the mean birth length and the mean height standard deviation scores in the 2nd and 6th years of life. The mean final height is expressed in cm and as mean standard deviation score. We calculated the target height, estimated from parental heights, for those who have attained final height. The standard deviation for each calculation is shown.

All patients who received hormonal treatment to limit their adult height were excluded from the final height data.

Results

FACIES
The typical long thin adult facies of patients with Sotos syndrome are shown in fig 1.

GROWTH
Growth data on 40 patients (20 female and 20 male) aged 2 to 31 years were collected and are summarised in table 1. Two women and one man were excluded from the final height data as they had received hormonal treatment to limit their final height.
The mean (SD) birth lengths of the boys and girls were 55.6 (2.8) cm and 57.3 (3.5) cm, respectively. In boys, the mean (SD) height standard deviation scores in the 2nd and 6th years were 3.58 (1.2) and 3.0 (0.084), respectively. The mean (SD) height standard deviation scores for girls in the 2nd and 6th years were 3.6 (0.08) and 3.8 (1.1), respectively.

The mean (SD) height standard deviation scores achieved at attainment of final height were only 1.51 (0.08) for the men and 1.8 (0.17) for the women. The final height and target height were available for only nine men. The mean target height in these cases was 173 cm compared with the population mean of 175.5 cm, whereas in women the target height was 3.2 cm above the population mean (166.7 cm v 163.5 cm). However, the final height in the men was an average of 11.3 cm greater than the target height compared with only 6.2 cm in the women (table 1).

**Table 1 Growth analysis in patients with Sotos syndrome**

<table>
<thead>
<tr>
<th></th>
<th>MBL (cm)</th>
<th>HtSDS2</th>
<th>HtSDS6</th>
<th>FHtSDS</th>
<th>FHt (cm)</th>
<th>THt (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>55.5 (2.8)</td>
<td>3.58 (1.2)</td>
<td>3.0 (0.84)</td>
<td>1.51 (0.08)</td>
<td>184.3 (6.0)</td>
<td>173 (6.3)</td>
</tr>
<tr>
<td>Female</td>
<td>57.3 (3.5)</td>
<td>3.6 (0.08)</td>
<td>3.8 (1.1)</td>
<td>1.8 (1.17)</td>
<td>172.9 (5.7)</td>
<td>166.7 (5)</td>
</tr>
</tbody>
</table>

All values are mean (SD).

MBL, mean birth length; HtSDS2, mean height standard deviation score in the 2nd year of life; HtSDS6, mean height standard deviation score in the 6th year of life; FHtSDS, final height standard deviation score; FHt, final height; THt, target height.

 uso del tratamiento de Sotos. (Todas las fotografías reproducidas con el consentimiento de los pacientes.)

**Figura 1** Caras típicas de los niños con tratamiento de Sotos. (Todas las fotografías reproducidas con el consentimiento de los pacientes.)

The mean (SD) height standard deviation scores achieved at attainment of final height were only 1.51 (0.08) for the men and 1.8 (0.17) for the women. The final height and target height were available for only nine men. The mean target height in these cases was 173 cm compared with the population mean of 175.5 cm, whereas in women the target height was 3.2 cm above the population mean (166.7 cm v 163.5 cm). However, the final height in the men was an average of 11.3 cm greater than the target height compared with only 6.2 cm in the women (table 1).

**Table 1 Growth analysis in patients with Sotos syndrome**

<table>
<thead>
<tr>
<th></th>
<th>MBL (cm)</th>
<th>HtSDS2</th>
<th>HtSDS6</th>
<th>FHtSDS</th>
<th>FHt (cm)</th>
<th>THt (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>55.5 (2.8)</td>
<td>3.58 (1.2)</td>
<td>3.0 (0.84)</td>
<td>1.51 (0.08)</td>
<td>184.3 (6.0)</td>
<td>173 (6.3)</td>
</tr>
<tr>
<td>Female</td>
<td>57.3 (3.5)</td>
<td>3.6 (0.08)</td>
<td>3.8 (1.1)</td>
<td>1.8 (1.17)</td>
<td>172.9 (5.7)</td>
<td>166.7 (5)</td>
</tr>
</tbody>
</table>

All values are mean (SD).

MBL, mean birth length; HtSDS2, mean height standard deviation score in the 2nd year of life; HtSDS6, mean height standard deviation score in the 6th year of life; FHtSDS, final height standard deviation score; FHt, final height; THt, target height.

**Figura 1** Caras típicas de los niños con tratamiento de Sotos. (Todas las fotografías reproducidas con el consentimiento de los pacientes.)

The mean (SD) height standard deviation scores achieved at attainment of final height were only 1.51 (0.08) for the men and 1.8 (0.17) for the women. The final height and target height were available for only nine men. The mean target height in these cases was 173 cm compared with the population mean of 175.5 cm, whereas in women the target height was 3.2 cm above the population mean (166.7 cm v 163.5 cm). However, the final height in the men was an average of 11.3 cm greater than the target height compared with only 6.2 cm in the women (table 1).

**Table 1 Growth analysis in patients with Sotos syndrome**

<table>
<thead>
<tr>
<th></th>
<th>MBL (cm)</th>
<th>HtSDS2</th>
<th>HtSDS6</th>
<th>FHtSDS</th>
<th>FHt (cm)</th>
<th>THt (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>55.5 (2.8)</td>
<td>3.58 (1.2)</td>
<td>3.0 (0.84)</td>
<td>1.51 (0.08)</td>
<td>184.3 (6.0)</td>
<td>173 (6.3)</td>
</tr>
<tr>
<td>Female</td>
<td>57.3 (3.5)</td>
<td>3.6 (0.08)</td>
<td>3.8 (1.1)</td>
<td>1.8 (1.17)</td>
<td>172.9 (5.7)</td>
<td>166.7 (5)</td>
</tr>
</tbody>
</table>

All values are mean (SD).

MBL, mean birth length; HtSDS2, mean height standard deviation score in the 2nd year of life; HtSDS6, mean height standard deviation score in the 6th year of life; FHtSDS, final height standard deviation score; FHt, final height; THt, target height.

**Figura 2** Espalda de pacientes con síndrome de Sotos comparada con valores normales de edad y sexo.

**Figura 3** Proporción de segmento de cuerpo superior a inferior en pacientes con síndrome de Sotos comparada con valores normales de edad y sexo.

The span and upper to lower segment ratio are plotted on charts indicating normal values for age and sex (figs 2 and 3). The upper to lower segment ratio was reduced in patients with Sotos syndrome whereas the arm span was increased.

**BONE AGE IN SOTOS SYNDROME**

Twenty seven x rays (from 13 patients) were available for rating. Bone age was advanced in
all patients. In about three quarters of the patients it was advanced more than the 97th centile for age.

**AGE OF MENARCHE**

Mean (SD) age of menarche was 12.2 (1.8) years (n = 12). There was, however, a wide range (8.9–15.4 years) with the median age being 12 years.

**Discussion**

The mean birth length of our cohort was increased. Growth remained excessive leading to tall stature (height well above the 97th centile) in the 2nd and 6th years of life. The excessive early growth of our cohort is in agreement with that reported previously. Using the “infancy–childhood–puberty model”, showed that the growth rate in infancy in children with Sotos syndrome was significantly increased. This was also associated with later onset of the childhood component of growth. Mean height velocity during the childhood component was similar to controls. Therefore, this pattern of growth leads to a height consistently above the 97th centile in infancy and childhood.

The women had a mean final height within the normal range for the British population. The mean final height for the men was also usually within the normal range, although exceptions to this were more likely than in women. The final heights achieved by both sexes, although within the normal range, were significantly more than their calculated target heights. The women had a target height above the 50th centile whereas the men had a target height below the 50th centile. Furthermore the mean excess in final height compared with target height was greater in the men (11.3 cm) than the women (6.2 cm). This suggests that the final height is more likely to exceed the 97th centile in men with Sotos syndrome than women, although familial growth patterns need to be considered in these estimations.

The age of onset of menarche in most of our postpubertal girls appeared to be early compared with the average age of onset in British girls, which is 13 years, although the difference did not reach significance, probably because of the small numbers. The combination of advanced bone age and a tendency to early onset of menarche probably led to a final height in the women, which was on or below the 97th centile. It is important to point out that even the two girls who had a later onset of menarche (at 14 and 15.4 years) did not end up excessively tall.

The excess of span for age and the reduced upper to lower segment body ratio showed that much of the influence on height is a result of limb length.

Endocrinological investigations have not provided an explanation for this growth pattern. There have been individual reports of patients with either hyperthyroidism or hypothyroidism, but these have been infrequent. Hook et al showed that growth hormone concentrations were adequately suppressed in five of six patients after an oral glucose tolerance test. These patients also had a normal increase in growth hormone in response to hypoglycaemia. Reports of insulin-like growth factor I (IGF-I) and IGF-II concentrations have not shown a constant pattern. Amber et al showed that the mean overnight growth hormone concentration of a child with Sotos syndrome aged 1.7 years was high, at 24.6 mU/L. The growth hormone profiles also showed an incomplete return to baseline between pulses. At the age of 3.3 years, the mean serum overnight growth hormone concentrations reduced to 11.5 mU/L, and return to baseline between pulses was more evident. The mean serum overnight hormone concentrations in other patients with Sotos syndrome who were pubertal were only 4.7 mU/L and 4.2 mU/L, respectively. These findings will need to be repeated in a larger number of patients with Sotos syndrome (compared with age and height matched controls) before this can be assumed to be the explanation for the growth pattern in this syndrome.

Other overgrowth syndromes exist and these have occasionally been wrongly diagnosed as Sotos syndrome. In our study, all the patients recruited were examined by the same clinical geneticist with expertise in the syndrome, increasing the likelihood that the data are from a homogenous group.

The potential of gigantism adult height stature is the main reason for offering hormonal treatment (oestrogen/testosterone or somatostatin) to limit final adult height. Our study has shown that most patients with Sotos syndrome (especially girls) do not require any intervention to limit adult height.

Lorenzo’s oil: the sequel

The film *Lorenzo’s Oil* dramatically illustrated the predicament of families where there is a child with an untreatable inherited metabolic disease. The oil devised as treatment by the father of a child with X-linked adrenoleukodystrophy (X-ALD) has proved disappointing but new research (Stephen Kemp and colleagues. *Nature Medicine* 1998;4:1261–8. See also News and Views, pages 1245–6) brings hope of effective treatment and illustrates a new direction in gene therapy.

There are probably many redundant genes in animal and human cells, which have the capacity to bring into play alternative metabolic pathways. Chemical agents are capable of stimulating the expression of such genes and investigators at Johns Hopkins University have shown that 4-phenylbutyrate (4PBA) may be such an agent for X-ALD cells.

The defect in X-ALD is in the gene encoding the peroxisomal membrane protein, ALDP (adrenoleukodystrophy protein). What the Baltimore researchers have shown is that 4PBA treatment of X-ALD fibroblasts induces the expression of the ALD related protein (ALDRP) gene, causes peroxisomal proliferation, and results in increased β oxidation of very long chain fatty acids (VLCFA). When they gave 4PBA to X-ALD mice there was a substantial fall in VLCFA (almost to normal) in brain and adrenal glands. Trials in patients with X-ALD seem called for.

The effects of 4PBA may not be restricted to X-ALD. It has been used to promote fetal haemoglobin production in haemoglobinopathies and to stimulate the aberrant CFTR gene in cystic fibrosis. The awakening of dormant genes seems an exciting possibility but clearly excitement must not be allowed to run ahead of the facts.
Growth in Sotos syndrome

J C Agwu, N J Shaw, J Kirk, S Chapman, D Ravine and T R P Cole

Arch Dis Child 1999 80: 339-342
doi: 10.1136/adc.80.4.339

Updated information and services can be found at:
http://adc.bmj.com/content/80/4/339

These include:

References
This article cites 14 articles, 3 of which you can access for free at:
http://adc.bmj.com/content/80/4/339#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Reproductive medicine (945)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/